Ones To Watch News
Refine search
Biotechnology
US biotech 4D Molecular Therapeutics has reported positive two-year data from the Phase IIb PRISM trial of 4D-150, its investigational intravitreal gene therapy for wet age-related macular degeneration (wet AMD). 20 July 2026
Biotechnology
USA-based BlossomHill Therapeutics has become the sixth biotech to line up for a stock market debut in July, filing to go public as investor enthusiasm for new drug listings shows little sign of cooling. The San Diego oncology specialist has applied to list on the Nasdaq Global Select Market under the ticker BLSM. 20 July 2026
Biotechnology
USA-based biotech Latigo Biotherapeutics has thrown open its books to public investors, using a Friday filing with the Securities and Exchange Commission to reveal mid-stage results for its lead non-opioid pain candidate LTG-001 while laying out plans to raise fresh capital through a stock market debut. 20 July 2026
Biotechnology
Canadian genetic medicines company enGene Therapeutics announced changes to its board of directors as it prepares for potential regulatory milestones and commercial readiness for its investigational gene therapy, detalimogene voraplasmid, if approved. 17 July 2026
Biotechnology
UK biotech company Mission Therapeutics has agreed to hand its acute kidney injury candidate MTX652 to Australian renal specialist Dimerix in a deal that could bring the Cambridge-based firm up to $292 million, freeing it to concentrate on a central nervous system pipeline led by a Parkinson's disease drug. 17 July 2026
Biotechnology
US biotech Jasper Therapeutics has completed its all-stock acquisition of complement-focused Kira Pharmaceuticals, creating a combined immunology company with a broader biologics pipeline for immune-mediated diseases. 17 July 2026
Biotechnology
Chinese biotech InnoCare Pharma has reported positive top-line Phase II data for its oral TYK2 inhibitor soficitinib (ICP-332) in adults with nonsegmental vitiligo. 17 July 2026
Pharmaceutical
Arrowhead Pharmaceuticals has recently announced that the European Commission has granted marketing authorization for Redemplo (plozasiran), an innovative apolipoprotein C III (apoC-III) inhibitor that is already approved in the USA for the treatment of adults with familial chylomicronemia syndrome (FCS). 17 July 2026
Biotechnology
China’s Insilico Medicine , a leader in clinical-stage generative AI for drug discovery, has announced a multi-target strategic alliance with Taiwan’s Bora Pharmaceuticals.
. 17 July 2026
Biotechnology
USA-based biotech company Prolynx has expanded its senior leadership, appointing Simon Harnest as chief financial officer and Amer Mirza as chief scientific officer, as the Emeryville, California, firm pushes a portfolio of long-acting obesity and metabolic disease candidates toward first-in-human testing. 16 July 2026
Biotechnology
Australian radiopharmaceutical company AdvanCell has closed an oversubscribed and upsized $315 million Series D financing to advance its targeted alpha therapy pipeline and expand its manufacturing network. 15 July 2026
Biotechnology
The German-listed group behind personalized-genetics firm Novogenia has taken its best-known brand as its corporate name, a move it says unifies identity without changing strategy. 15 July 2026
Biotechnology
USA-based biotech Celcuity has won its first US Food and Drug Administration (FDA) approval, with the regulator clearing Revtorpyk (gedatolisib) for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer without a detected PIK3CA mutation, following progression on or after at least one line of endocrine therapy in the metastatic setting. 15 July 2026
Pharmaceutical
US companies NextCure and privately-held biotech Avere Therapeutics, which is advancing oral therapies for interleukin (IL)-23 driven inflammatory diseases, have entered into a definitive merger agreement for an all-stock transaction. 15 July 2026
Pharmaceutical
US AI drug discovery firm Chai Discovery has raised $400 million in a Series C financing, valuing the San Francisco-based company at $3.8 billion as it looks to expand use of its molecular design platform across the pharma industry. 15 July 2026
Biotechnology
Cambridge, USA-based biotech Spero Therapeutics on Tuesday announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of KKR. 15 July 2026
Biotechnology
US commercial-stage biotech Mighty Therapeutics today announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. 14 July 2026
Pharmaceutical
Clinical-stage biopharmaceutical company Draig Therapeutics has closed an oversubscribed $65 million Series B financing to support development of its neuropsychiatry pipeline, led by the Phase II major depressive disorder candidate DT-101. 14 July 2026
Pharmaceutical
UK headquartered ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights in the respiratory clinical development space, has completed a major corporate repositioning and reorganization. The move marks the next stage of the company's development. 14 July 2026
Biotechnology
Germany’s speciality chemicals company Evonik has partnered with global antibody expression specialist evitria to offer a ready-to-use transient protein expression kit based on CHO cells for biopharmaceutical research and development. 14 July 2026
Pharmaceutical
California-based obesity-focused clinical-stage pharma Aardvark Therapeutics saw its shares tumble nearly 26% to $4.99, after it announced that the US Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the company’s previously announced voluntary pause. 15 May 2026
Biotechnology
CREATE Medicines has raised $122 million in a Series B financing round to support development of its in vivo CAR-T pipeline across autoimmune disease and oncology, as investor interest continues to grow around next-generation cell therapies. 15 May 2026
Biotechnology
China-headquartered Degron Therapeutics, a biotech advancing molecular glue degrader (MGD) medicines targeting previously undruggable or insufficiently drugged proteins, has announced the closing of a $40 million Series A extension. 14 May 2026
Pharmaceutical
US regulator the Food and Drug Administration has granted accelerated approval to Beqalzi (sonrotoclax), giving BeOne Medicines its first regulatory clearance for the next-generation BCL-2 inhibitor. 14 May 2026
Biotechnology
Servier Ventures, the VC fund created by the French drugmaker, has selected Cytospire Therapeutics for its first investment. 13 May 2026
Biotechnology
Boehringer Ingelheim and US clinical-stage drug developer Immunitas Therapeutics have announced a global licensing agreement for a pre-clinical antibody program being developed for chronic inflammatory and autoimmune diseases. 13 May 2026
Biotechnology
UK based clinical-stage biotech Artios Pharma announced a clinical trial collaboration and supply agreement with UK pharma major GSK to evaluate alnodesertib, Artios’ ATR inhibitor, in combination with risvutatug rezetecan (also referred to as Ris-Rez). 13 May 2026
Biotechnology
Privately-held Boston, USA, firm Cellular Intelligence has acquired global rights to Novo Nordisk's cell therapy program for Parkinson's disease. 12 May 2026
Biotechnology
US biotech Inhibrx Biosciences has reported encouraging mid-stage data for its OX40 agonist INBRX-106, showing the drug significantly improved response rates when added to Merck & Co’s Keytruda (pembrolizumab) in first-line head and neck cancer. 12 May 2026
Biotechnology
German biotech Exciva GmbH, which is developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the appointment of Mark Altmeyer as chairman of its board of directors. 12 May 2026
Pharmaceutical
Japanese drugmaker Nxera Pharma has entered into a license agreement with a newly established company (NewCo) to advance a specific GPCR-targeted program owned by Nxera. Nxera shares rose 6.4% to 1,242 yen on the news. 11 May 2026
Biotechnology
US clinical-stage biotech Odyssey Therapeutics has raised around $304 million through an upsized initial public offering and concurrent private placement, giving the autoimmune specialist a stronger-than-expected return to public markets. 11 May 2026
Biotechnology
The US Food and Drug Administration (FDA) late Friday approved a label expansion for Netherlands-based argenx’ Vyvgart efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG). 9 May 2026
Pharmaceutical
US biotech startup ParcelBio has emerged from stealth with a $13 million seed financing aimed at overcoming one of the key biological constraints limiting broader use of mRNA medicines beyond vaccines and short-acting therapies. 8 May 2026
Pharmaceutical
British pharma major AstraZeneca is expanding its oncology-focused artificial intelligence collaboration with US biotech Immunai in a deal that could bring the smaller company up to $37.5 million over 2026-2027. 8 May 2026
Biotechnology
Avalo Therapeutics’ shares surged 34%, after the US clinical-stage biotech announced positive top-line results from its Phase II LOTUS trial evaluating the efficacy and safety of abdakibart in adults with moderate to severe hidradenitis suppurativa (HS). 8 May 2026
Biotechnology
Canadian genetic medicines company enGene Therapeutics reported additional interim results from the pivotal cohort of its ongoing, Phase II LEGEND trial of detalimogene voraplasmid (also known as detalimogene) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without concomitant papillary disease, which enrolled 125 patients. 8 May 2026
Biotechnology
Full-stack spatial biology company Kanvas Biosciences has raised $48 million in a Series A funding round. 7 May 2026
Biotechnology
US oncology company Citius Oncology has secured up to $36.5 million in new financing as it attempts to accelerate the rollout of Lymphir (denileukin diftitox-cxdl), its recently launched therapy for relapsed or refractory cutaneous T-cell lymphoma. 7 May 2026
Pharmaceutical
British drugmaker GSK is paying up to $1 billion to partner with China’s Siran Biotechnology on an experimental gene-silencing therapy designed to reduce visceral fat, reflecting a growing industry shift beyond simple weight loss. 7 May 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze